~5 seconds
Rapid disintegration
RITe™ tablets disintegrate in roughly five seconds.
Orcosa · Clinical-stage pharmaceuticals
Modernizing
the way medicines
are taken.
We are developing medicines with the people who take them in mind. Our proprietary RITe™ technology brings a different approach to the familiar tablet.
People at the heart of our work
Different generations.
Everyday needs.
The experience of taking medicine can matter just as much as the medicine itself.
For a child who struggles with pills, an older adult who has difficulty swallowing, a caregiver helping a loved one take a dose, or a person looking for relief from an everyday ailment, our technology is designed to make treatment simpler, faster, and easier to fit into everyday life.
Our companyMeet RITe™
A small tablet.
A different approach.
Our tablet technology combines rapid disintegration with a defined unit dose to produce formulations tailored to the medicine and the people taking it.
1
A defined dose
A dose formulated into each individual tablet, with no liquid to measure.
0
No water required
Designed to be taken without water or swallowing an intact pill.
Our medicines in development
Investigational · Acute painAdvancing our
Advancing our
lead medicine.
ORC-144
Cannabidiol orally disintegrating tablet
We are developing ORC-144, our investigational cannabidiol tablet, as a new non-opioid approach to acute pain in adults.
Explore our pipelineOrcosa’s product candidates are investigational and have not been approved by the FDA. Their safety and effectiveness for the uses under investigation have not been established.
Our science
Research that informs
our medicines.
A randomized study after rotator cuff repair
Clinical research with ORC-144, Orcosa’s investigational CBD tablet, following shoulder surgery.
Follow-up after postoperative treatment
One-year follow-up examining recovery and shoulder outcomes after treatment with ORC-144.
Built to develop medicines
The science. The people.
The capabilities.
Our team brings pharmaceutical development, clinical experience, and in-house formulation and manufacturing capabilities together to advance our medicines.
Formulation
Designing tablets around the active ingredient and the way a medicine is taken.
Development
Connecting formulation science, analytical development, and clinical research.
Manufacturing
Developing the processes behind our investigational medicines.
Company news
The latest from Orcosa.
May 6, 2026
Andy Drechsler joins Orcosa as Chief Financial Officer
Expanding Orcosa’s leadership team with life sciences finance experience.
Read the announcement